papillomavirus induced cervical carcinoma gene therapy (Harvard University/Harvard University Office of Technology Development)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namepapillomavirus induced cervical carcinoma gene therapy (Harvard University/Harvard University Office of Technology Development)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant polypeptideCell and gene therapy > Gene therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsUterine Cervical NeoplasmsPapillomavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHarvard University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHarvard University
Active IndicationsN/A
Inactive IndicationsUterine Cervical NeoplasmsPapillomavirus Infections

Other Information

ATC CodeN/A
Related LinksN/A